![]() |
市場調査レポート
商品コード
1519474
薬物スクリーニング市場レポート:製品・サービス、サンプルタイプ、エンドユーザー、地域別、2024~2032年Drug Screening Market Report by Product and Service, Sample Type, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
薬物スクリーニング市場レポート:製品・サービス、サンプルタイプ、エンドユーザー、地域別、2024~2032年 |
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2~3営業日
|
世界の薬剤スクリーニング市場規模は2023年に64億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけて6.7%の成長率(CAGR)を示し、2032年には117億米ドルに達すると予測しています。麻薬密売人や地元ディーラーの増加、薬剤乱用の増加、仮想通貨利用の増加が薬剤スクリーニング市場の成長を促進する主要要因となっています。
主要市場促進要因:薬剤スクリーニングは正確であり、自発的に結果が得られるため、その需要の増加が主に市場の成長を促進しています。さらに、世界中で薬剤乱用の事例が増加していることも世界市場を促進しています。
主要市場動向:自動化、人工知能(AI)、分子診断などの先端技術を薬剤スクリーニング試験に統合することで、ワークフローを合理化し、人為的ミスを減らし、試験を強化することが、重要な主要動向の1つとして作用し、市場の成長を後押ししています。
競合情勢:薬剤スクリーニング市場の主要企業には、Abbott Laboratories、Alfa Scientific Designs Inc.、Bio-Rad Laboratories Inc.、Dragerwerk AG &Co.KGaA、Laboratory Corporation of America Holdings、Lifeloc Technologies Inc.、Omega Laboratories Inc.、OraSure Technologies Inc.、Psychemedics Corporation、Quest Diagnostics Incorporated、Siemens AG、Thermo Fisher Scientific Inc.などが挙げられます。
地理的動向:報告書によると、北米は薬剤スクリーニングの最大市場です。この地域の成長は、薬剤乱用の深刻化、薬剤売人の増加、処方された薬剤の闇取引の増加に起因しています。
課題と機会:薬剤スクリーニング市場は、正確で信頼性の高い試験の開発、偽陽性・偽陰性の克服、サンプル採取と試験手順に関するプライバシーと倫理的懸念への対応に関するハードルに直面しています。データ解析のためのAIや機械学習などの先進技術の統合や、便利で迅速なスクリーニング用途のための携帯型試験機器やポイントオブケア試験機器の開発に機会があります。
薬剤・アルコール消費の増加
薬剤消費の増加は、薬剤スクリーニング製品に対する需要の増加をもたらしています。例えば、2023 European Drug Reportによると、欧州連合(EU)の成人約8,340万人(29%)が違法薬剤を一度でも使用したことがあると報告されています。大麻は欧州で消費される主要な違法薬剤であり、各国の調査によると、2022年には欧州成人の8%が使用していると推定されています。このように、多くの人口が薬剤を消費しており、個人の生活に影響を与え、薬剤スクリーニングの需要を増加させる可能性が高いため、薬剤スクリーニング市場の最近の価格を強化しています。さらに、治療の必要性とともに、薬剤やアルコールの利用が増加しているため、病院での薬剤スクリーニングの需要が増加すると予想されています。例えば、GOV.UKが発表した国家統計によると、2023年12月、2022年4月から2023年3月までの間に、約29万635人の成人が薬剤使用問題のサポートを受けた。これは、前年の約28万9,215人と比べてわずかな増加です。さらに、同じ情報源によれば、2022~2023年にかけて治療に入った成人の数は約13万7,749人で、前2年の13万490人、13万3,704人を上回っています。このような薬剤使用中の人々の大幅な増加は、薬剤スクリーニング市場の需要を促進すると予想されます。
政府規制
さまざまなセグメントで薬剤・アルコール試験が義務付けられている法律や規制がいくつかあり、こうした法律の施行が薬剤試験製品や装置の需要を増大させています。例えば、2022年11月、連邦自動車運送安全局(FMCSA)は、薬剤・アルコール試験要件概要を示す更新を発表しました。これらの規制は、試験の対象となる個人、試験の頻度、試験のきっかけとなる状況を規定しています。さらに、雇用主やサービス代理店による薬剤・アルコール試験の機密情報の使用や開示を制限することで、従業員のプライバシーを保護しています。規制の枠組み以外にも、各国の政府当局は重度の中毒者や薬剤乱用に苦しむ人々を支援する取り組みを行っており、これが薬剤スクリーニング市場のシェアをさらに押し上げています。例えば、Nasha Mukt Bharat Abhiyaanはインド政府によるプログラムで、大衆に手を差し伸べ、意識向上プログラムのような様々な活動を通じて薬剤乱用に関する意識を広めることを意図しています。同様に、カナダの政府当局も、薬剤依存症患者が薬剤乱用から抜け出せるよう、薬剤対策プロジェクトに投資しています。例えば、カナダのアルバータ州にあるCalgary John Howard Societyでは、薬剤中毒によって学校中退の危機に直面している13歳から24歳の若者の支援に力を入れています。
試験技術の進歩
迅速試験キット、実験室ベースのアッセイ、ポイント・オブ・ケア機器など、薬剤スクリーニング技術の継続的な進歩は、より迅速で正確、かつ費用対効果の高いスクリーニングソリューションを提供することで、市場の成長をさらに促進しています。さらに、薬剤スクリーニング技術の継続的な改善により、精度と信頼性が向上し、偽陽性や偽陰性の可能性が減少しているため、試験結果に対する信頼性が確保され、確認試験の必要性が最小化されるため、スクリーニングプロセスが合理化され、コストが削減されます。例えば、2024年2月、Mobile Healthは、ニューヨークのクリニックで、雇用主が候補者を簡単にスクリーニングして雇用できる新しい迅速薬剤試験サービスを導入しました。同様に、2023年10月、ProciseDx Inc.は、アダリムマブ(ヒュミラとバイオシミラーAmgevita)とインフリキシマブ(レミケードとバイオシミラーInflectraとRenflexis)の治療物モニタリング(TDM)試験の新規FDA許可を取得しました。Procise ADLとProcise IFXと呼ばれるこれらのアッセイは、これらの薬剤を服用中の炎症性腸疾患(IBD)患者におけるアダリムマブ(ADL)とインフリキシマブ(IFX)の定量に使用されます。新しい薬剤試験や機器の承認が増加しており、今後数年間で薬剤スクリーニング市場の収益を促進すると予想されます。
The global drug screening market size reached US$ 6.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032. The growing number of drug traffickers and local dealers, rising cases of substance abuse, and increasing employment of virtual currencies represent some of the key factors driving the drug screening market growth.
Major Market Drivers: Increasing demand for drug screening as it is accurate and provides spontaneous results is primarily driving the growth of the market. Furthermore, the rising cases of substance abuse around the world are also propelling the global market.
Key Market Trends: The integration of advanced technologies such as automation, artificial intelligence (AI), and molecular diagnostics with drug screening tests to streamline workflows, reduce human errors, and enhance testing is acting as one of the significant key trends, bolstering the market growth.
Competitive Landscape: Some of the leading drug screening market companies include Abbott Laboratories, Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Dragerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Lifeloc Technologies Inc., Omega Laboratories Inc., OraSure Technologies Inc., Psychemedics Corporation, Quest Diagnostics Incorporated, Siemens AG, and Thermo Fisher Scientific Inc., among others.
Geographical Trends: According to the report, North America is the largest market for drug screening. The growth of the region can be attributed to the escalating cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs.
Challenges and Opportunities: The drug screening market faces hurdles related to the development of accurate and reliable tests, overcoming false positives and negatives, and addressing privacy and ethical concerns regarding sample collection and testing procedures. Opportunities lie in the integration of advanced technologies such as AI and machine learning for data analysis and the development of portable and point-of-care testing devices for convenient and rapid screening applications.
Rise in Drug and Alcohol Consumption
The increasing consumption of drugs is resulting in an increased demand for drug-screening products. For instance, according to the 2023 European Drug Report, approximately 83.4 million adults (29%) in the European Union have reportedly used illicit drugs at least once. Cannabis is the predominant illicit drug consumed in Europe, with an estimated 8% of European adults using it in 2022, based on national surveys. Thus, a high number of the population consumes drugs, which impacts the lives of individuals and is likely to increase demand for drug screening, thereby bolstering the drug screening market's recent price. Additionally, the rising utilization of drugs and alcohol, along with the need for treatment, is anticipated to drive up the demand for drug screening in hospitals. For instance, as per National statistics published by GOV. UK, in December 2023, between April 2022 and March 2023, around 290,635 adults received support for substance use issues. This is a small rise compared to the previous year, around 289,215. Moreover, the same source stated that the number of adults entering treatment from 2022 to 2023 was approx. 137,749, which is higher than the previous two years' figures of 130,490 and 133,704. Such a significant rise in the number of people undergoing substance use is anticipated to propel the drug screening market demand.
Government Regulations
Several laws and regulations mandate drug and alcohol testing in various sectors, and the implementation of such laws is augmenting the demand for drug-screening products and devices. For instance, in November 2022, the Federal Motor Carrier Safety Administration (FMCSA) released updates outlining the drug and alcohol testing requirements. These regulations specify the individuals subject to testing, the frequency of testing, and the circumstances triggering testing. Additionally, the regulations safeguard employee privacy by limiting the use and disclosure of sensitive drug and alcohol testing information by employers and service agents. Besides the regulatory framework, government authorities of various nations are also taking initiatives to help severe addicts and individuals suffering from drug abuse, which is further propelling the drug screening market share. For instance, Nasha Mukt Bharat Abhiyaan is a program by the Indian Government that intends to reach out to the masses and spread awareness about substance abuse through various activities like awareness generation programs. Similarly, the government authorities of Canada are also investing in anti-drug strategy projects to help people with addiction come out of substance abuse. For example, the Calgary John Howard Society in Alberta, Canada, focuses on assisting youths aged 13 to 24 who face the risk of school dropout due to drug addiction.
Advancements in Testing Technologies
Ongoing advancements in drug screening technologies, such as rapid testing kits, laboratory-based assays, and point-of-care devices, are further driving the market growth by offering faster, more accurate, and cost-effective screening solutions. Moreover, the continuous improvement of drug screening technologies is resulting in enhanced accuracy and reliability and reduced likelihood of false positives or false negatives, ensuring confidence in test results and minimizing the need for confirmatory testing, thereby streamlining the screening process and reducing costs. For instance, in February 2024, Mobile Health introduced a new rapid drug testing service in New York clinics for employers to screen and hire candidates easily. Similarly, in October 2023, ProciseDx Inc. received de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira and biosimilar Amgevita) and infliximab (Remicade and biosimilars Inflectra and Renflexis). These assays, called Procise ADL and Procise IFX, are used to quantify adalimumab (ADL) and infliximab (IFX) in patients suffering from inflammatory bowel diseases (IBD) who are taking these drugs. Increasing approval of new drug tests and instruments is anticipated to propel the drug screening market revenue in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global drug screening market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product and service, sample type, and end user.
Equipment
Immunoassay Analyzers
Chromatography Instruments
Breath Analyzers
Rapid Testing Devices
Urine Testing Devices
Oral Fluid Testing Devices
Consumables
Assay Kits
Sample Collection Cups
Calibrators and Controls
Others
Laboratory Services
Rapid testing devices represented the largest segment
The drug screening market report has provided a detailed breakup and analysis of the drug screening market based on the product and service. This includes equipment (immunoassay analyzers, chromatography instruments, and breath analyzers); rapid testing devices (urine testing devices and oral fluid testing devices); consumables (assay kits, sample collection cups, calibrators and controls, and others); and laboratory services. According to the report, rapid testing devices (urine testing devices and oral fluid testing devices) represented the largest segment.
Rapid drug screening test devices are portable, easy-to-use tools designed for quick detection of drugs in various sample types, such as urine, saliva, or blood. These devices offer several benefits, including rapid results within minutes, enabling on-the-spot decision-making in scenarios like workplace testing or roadside screening. Their simplicity allows for minimal training requirements, making them accessible to a wide range of users. Moreover, rapid tests are cost-effective, reducing the need for laboratory analysis and turnaround time. For instance, Drager, a German company based in Lubeck that makes breathing and protection equipment, gas detection and analysis systems, and non-invasive patient monitoring technologies, introduced a rapid test named DrugTest 5000. In this test, saliva samples can be analyzed immediately for an accurate result on the spot. Furthermore, rapid screening devices play a crucial role in emergencies, aiding in the quick identification of drug intoxication or overdose for prompt medical intervention.
Urine Samples
Breath Samples
Oral Fluid Samples
Hair Samples
Others
Urine samples accounted for the largest market share
A detailed breakup and analysis of the drug screening market based on the sample type has also been provided in the report. This includes urine samples, breath samples, oral fluid samples, hair samples, and others. According to the report, urine samples accounted for the largest market share.
As per the drug screening market overview, urine sample drug testing offers several benefits, making it a preferred method over other sample types in many scenarios. Firstly, urine testing is non-invasive and relatively easy to collect, minimizing discomfort and ensuring employee cooperation. Secondly, urine samples can detect a wide range of drugs and their metabolites, providing comprehensive screening capabilities. Thirdly, urine testing is cost-effective and suitable for high-volume testing, making it practical for workplace screening programs. Furthermore, urine testing is capable of detecting recent drug use, making it suitable for detecting impairment in safety-sensitive industries. Lastly, this testing is less susceptible to adulteration or tampering compared to other sample types, ensuring the integrity and reliability of test results.
Hospitals
Drug Testing Laboratories
Workplaces
Drug Treatment Centers
Pain Management Centers
Personal Users
Criminal Justice System and Law Enforcement Agencies
Workplaces accounted for the largest market share
A detailed breakup and analysis of the drug screening market based on the end user has also been provided in the report. This includes hospitals, drug testing laboratories, workplaces, drug treatment centers, pain management centers, personal users, and criminal justice system and law enforcement agencies. According to the report, workplaces accounted for the largest market share.
Drug screening tests in workplaces are conducted to detect the presence of drugs or alcohol in employees. These tests are typically performed as part of pre-employment screening, random testing, post-accident testing, or reasonable suspicion testing. The aim is to ensure a safe and productive work environment, minimize the risk of accidents and injuries, and deter substance abuse among employees.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America (the United States and Canada) was the largest market for drug screening
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for drug screening.
Some of the factors driving the North America drug screening market included the growing cases of substance abuse, the increasing number of drug dealers, and the rising black marketing of prescribed drugs. Moreover, drug screening market statistics by IMARC indicate that the growing substance abuse rates in the region are bolstering the need for drug screening. For instance, in February 2023, according to an article published by the Pennsylvania State University, around 63% of adults aged 18 years and above were reported to alcohol consumption in the United States in 2022. Among these, males (66%) had higher alcohol consumption as compared to females (61%). Thus, the large number of alcohol consumers raises the need for drug-testing products and services and is augmenting the market growth in North America. Moreover, the government authorities of North America are mandating drug screening tests in various sectors, which is further catalyzing the market growth. For instance, in May 2023, the United States Department of Transportation regulated the drug testing program by including oral fluid testing to improve safety and reduce the chances of cheating involved with urine drug tests.
Abbott Laboratories
Alfa Scientific Designs Inc.
Bio-Rad Laboratories Inc.
Dragerwerk AG & Co. KGaA
Laboratory Corporation of America Holdings
Lifeloc Technologies Inc.
Omega Laboratories Inc.
OraSure Technologies Inc.
Psychemedics Corporation
Quest Diagnostics Incorporated
Siemens AG
Thermo Fisher Scientific Inc.
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
March 2024: bioXcelerate, a new and innovative health data science division of Optima Partners Limited, revealed a groundbreaking AI tool, which is set to accelerate the process of identifying and developing new drugs. The tool, known as PleioGraph, can analyze complex medical data 100 times faster than existing state-of-the-art methods used to detect biological networks that explain disease risk and inform drug discovery.
December 2023: Quest Diagnostics, one of the leading providers of diagnostic information services, unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.
October 2023: In India, Kerala police launched a rapid drug screening system that involves the utilization of a hand-held device, named the SoToxa Mobile Test System, and detects drug usage in 5 minutes.